All In Biotech

Investigational drug · Phase 2

Dispensing Codivir

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for HIV, HIV Infection.

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 6, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "Dispensing Codivir"

First trial start

2023

Jul 20, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Dispensing Codivir", any sponsor or status.

Conditions studied

As listed on its trial records.

  • HIV
  • HIV Infection

Approved drugs for the same conditions: Infectious disease and vaccines

Largest trials

Live from ClinicalTrials.gov: studies naming "Dispensing Codivir" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for HIV

  • AlimatravirMK-8527Phase 34 trials

    Merck & Co. · Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis, HIV

  • LipovirtidePhase 21 trial

    Shanxi Kangbao Biological Product Co., Ltd. · HIV

  • LP-98Phase 21 trial

    Shanxi Kangbao Biological Product Co., Ltd. · HIV

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.